Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. 4D Molecular Therapeutics, Inc.
  6. News
  7. Summary
    FDMT   US35104E1001

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
6.960 USD   -0.29%
06/244D MOLECULAR THERAPEUTICS, INC.(NASDAQGS : FDMT) dropped from Russell 2500 Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASDAQGS : FDMT) dropped from Russell 3000E Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASDAQGS : FDMT) dropped from Russell Microcap Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps Outperform Rating

05/13/2022 | 12:59pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about 4D MOLECULAR THERAPEUTICS, INC.
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 2500 Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 3000E Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell Microcap Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 3000 Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell Small Cap Comp Growth In..
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 2000 Growth Index
CI
06/22Jefferies Starts 4D Molecular Therapeutics at Buy With $22 Price Target
MT
06/214D MOLECULAR THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fisc..
AQ
06/214D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from S&P Biotechnology Select Industr..
CI
06/15TRANSCRIPT : 4D Molecular Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global ..
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 4,98 M - -
Net income 2022 -100 M - -
Net cash 2022 47,1 M - -
P/E ratio 2022 -2,22x
Yield 2022 -
Capitalization 225 M 225 M -
EV / Sales 2022 35,7x
EV / Sales 2023 25,9x
Nbr of Employees 137
Free-Float 88,4%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 6,96 $
Average target price 21,20 $
Spread / Average Target 205%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Fred Kamal Chief Technical Officer
Peter Francis SVP-Clinical Translational R&D
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-68.28%225
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.09%40 503
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.34%19 151